Express News | HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $18 Price Target
Instil Bio Is Maintained at Outperform by Baird
Instil Bio Is Maintained at Outperform by Baird
Express News | Baird Maintains Outperform on Instil Bio, Lowers Price Target to $32
Instil Bio, Inc. Q1 Loss Decreases
Instil Bio | 10-Q: Quarterly report
Express News | Instil Bio Q1 2024 GAAP EPS $(2.39) Misses $(2.23) Estimate
Express News | Instil Bio Inc - Cash Runway Expected Beyond 2026
Instil Bio 1Q Research and Development Expenses $7.3M >TIL
Instil Bio 1Q Research and Development Expenses $7.3M >TIL
Express News | Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Express News | Instil Bio Q1 Basic EPS USD -3.74
Instil Bio 1Q Loss/Shr $3.74 >TIL
Instil Bio 1Q Loss/Shr $3.74 >TIL
Press Release: Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-stage biopharmaceu
Instil Bio Announces Board Reshuffle Following Resignation
Instil Bio Cut to Hold From Buy by Jefferies
Instil Bio Cut to Hold From Buy by Jefferies
Express News | Jefferies Downgrades Instil Bio to Hold, Raises Price Target to $11
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Instil Bio (TIL) and Regeneron (REGN)
Express News | Instil Bio Inc : Jefferies Raises Target Price to $11 From $5
Express News | Instil Bio Inc : Jefferies Cuts to Hold From Buy
Express News | HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $18 Price Target
Instil Bio Non-GAAP EPS of -$1.26 Beats by $2.14